Skip to main content
Top
Published in: Cancer Causes & Control 12/2010

01-12-2010 | Original paper

The CCC National Partnership: an example of organizations collaborating on comprehensive cancer control

Authors: Karin Hohman, Phyllis Rochester, Tom Kean, Lori Belle-Isle

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

The landscape of cancer control has changed throughout the past 12 years and continues to change even more so as health reform is implemented in the United States. With the advent of health reform, coalitions, such as comprehensive cancer control (CCC) coalitions, are more important than ever if the intended benefits of reform are to be realized. Comprehensive cancer control (CCC) coalitions in state, tribe, territory, and Pacific Island Jurisdictions are “engines of change” and form a network that can facilitate important cancer control progress throughout this country. Since the onset of CCC efforts, the vitality of this network of coalitions and their sustainability has been the primary focus of a group of national organizations, now known as the Comprehensive Cancer Control National Partnership (CCCNP). The CCCNP is national organizations who come together voluntarily to develop strategies and resources that support implementation of CCC coalition plans across the nation.
Literature
5.
go back to reference Unpublished document: The National Partnership Comprehensive Cancer Control Strategic Plan 2008–2013 Unpublished document: The National Partnership Comprehensive Cancer Control Strategic Plan 2008–2013
Metadata
Title
The CCC National Partnership: an example of organizations collaborating on comprehensive cancer control
Authors
Karin Hohman
Phyllis Rochester
Tom Kean
Lori Belle-Isle
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9644-0

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine